Repeated administration of aripiprazole produces a sensitization effect in the suppression of avoidance responding and phencyclidine-induced hyperlocomotion and increases D2 receptor-mediated behavioral function

Journal of Psychopharmacology

Volumn 29, Issue 4, 2015, Pages 390-400

  Gao, Jun ^a   Qin, Rongyin ^a,b   Li, Ming ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Aripiprazole; conditioned avoidance response; phencyclidine; quinpirole; sensitization; tolerance

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; PHENCYCLIDINE; QUINPIROLE; NEUROLEPTIC AGENT;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR CHANGE; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG REEXPOSURE; DRUG SENSITIZATION; HYPERACTIVITY; LOCOMOTION; MALE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHOMOTOR ACTIVITY; RAT; REPEATED DRUG DOSE; ANIMAL; BRAIN; DRUG EFFECTS; HYPERKINESIS; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERKINESIS; MALE; PHENCYCLIDINE; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2;

EID: 84924941808     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114565937     Document Type: Article

References (64)

1. Agid O, Kapur S, Arenovich T, et al. Delayed-onset hypothesis of antipsychotic action: A hypothesis tested and rejected. Arch Gen Psychiatry. 2003 ; 60: 1228-1235
2. Aihara K, Shimada J, Miwa T, et al. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res. 2004 ; 1003: 9-17
3. Allen JA, Yost JM, Setola V, et al. Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A. 2011 ; 108: 18488-18493
4. Audet MC, Goulet S, Dore FY. Enhanced anxiety follows withdrawal from subchronic exposure to phencyclidine in rats. Behav Brain Res. 2007 ; 176: 358-361
5. Baird JP, Turgeon S, Wallman A, et al. Behavioral processes mediating phencyclidine-induced decreases in voluntary sucrose consumption. Pharmacol Biochem Behav. 2008 ; 88: 272-279
6. Barnes DE, Robinson B, Csernansky JG, et al. Sensitization versus tolerance to haloperidol-induced catalepsy: Multiple determinants. Pharmacol Biochem Behav. 1990 ; 36: 883-887
7. Bortolozzi A, Diaz-Mataix L, Toth M, et al. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl). 2007 ; 191: 745-758
8. Burda K, Czubak A, Kus K, et al. Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Pharmacol Rep. 2011 ; 63: 898-907
9. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002 ; 302: 381-389
10. Carli M, Calcagno E, Mainolfi P, et al. Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: Relationship with glutamate release in the medial prefrontal cortex. Psychopharmacology (Berl). 2011 ; 214: 639-652
11. Cosi C, Carilla-Durand E, Assie MB, et al. Partial agonist properties of the antipsychotics ssr181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol. 2006 ; 535: 135-144
12. Feng M, Sui N, Li M. Avoidance disruptive effect of clozapine and olanzapine is potentiated by increasing the test trials: Further test of the motivational salience hypothesis. Pharmacol Biochem Behav. 2012 ; 103: 467-473
13. Feng M, Sui N, Li M. Environmental and behavioral controls of the expression of clozapine tolerance: Evidence from a novel across-model transfer paradigm. Behav Brain Res. 2013 ; 238: 178-187
14. Gao J, Li M. Time-dependence of risperidone and asenapine sensitization and associated D2 receptor mechanism. Behav Brain Res. 2013 ; 257: 286-294
15. Gleason SD, Shannon HE. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl). 1997 ; 129: 79-84
16. Grayson B, Idris NF, Neill JC. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res. 2007 ; 184: 31-38
17. Hertel P, Olsen CK, Didriksen M, et al. Bifeprunox: A new and different antipsychotic. Schizophr Bull. 2005 ; 31: 301
18. Hirose T, Uwahodo Y, Yamada S, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol. 2004 ; 18: 375-383
19. Inoue A, Miki S, Seto M, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked gtpase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol. 1997 ; 321: 105-111
20. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-Ht1a receptor. Eur J Pharmacol. 2002 ; 441: 137-140
21. Kalinichev M, Robbins MJ, Hartfield EM, et al. Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: A locomotor activity and gene induction study. Prog Neuropsychopharmacol Biol Psychiatry. 2008 ; 32: 414-422
22. Kapur S, Agid O, Mizrahi R, et al. How antipsychotics work-from receptors to reality. NeuroRx. 2006 ; 3: 10-21
23. Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1h)-qui nolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther. 1995 ; 274: 329-336
24. Koller W, Herbster G, Anderson D, et al. Quinpirole hydrochloride, a potential anti-Parkinsonism drug. Neuropharmacology. 1987 ; 26: 1031-1036
25. Konradi C, Heckers S. Antipsychotic drugs and neuroplasticity: Insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry. 2001 ; 50: 729-742
26. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (Opc-14597) with dopamine and serotonin receptor Subtypes. Neuropsychopharmacology. 1999 ; 20: 612-627
27. Li M, Budin R, Fleming AS, et al. Effects of novel antipsychotics, amisulpiride and aripiprazole, on maternal behavior in rats. Psychopharmacology (Berl). 2005 ; 181: 600-610
28. Li M, Sun T, Mead A. Clozapine, but not olanzapine, disrupts conditioned avoidance response in rats by antagonizing 5-Ht(2a/2c) receptors. J Neural Transm. 2012 ; 119: 497-505
29. Li M, Sun T, Zhang C, et al. Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning. Psychopharmacology (Berl). 2010 ; 212: 45-57
30. Li Z, Ichikawa J, Dai J, et al. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol. 2004 ; 493: 75-83
31. Lieberman JA, Bymaster FP, Meltzer HY, et al. Antipsychotic drugs: Comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev. 2008 ; 60: 358-403
32. Luque-Rojas MJ, Galeano P, Suarez J, et al. Hyperactivity induced by the dopamine D2/D3 receptor agonist quinpirole is attenuated by inhibitors of endocannabinoid degradation in mice. Int J Neuropsychopharmacol. 2013 ; 16: 661-676
33. Mamo D, Graff A, Mizrahi R, et al. Differential effects of aripiprazole on D(2), 5-Ht(2), and 5-Ht(1a) receptor occupancy in patients with schizophrenia: A triple tracer pet Study. Am J Psychiatry. 2007 ; 164: 1411-1417
34. Mead A, Li M. Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: An interoceptive drug state mechanism. J Psychopharmacol. 2010 ; 24: 1045-1053
35. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 1989 ; 25: 390-392
36. Nakamura S, Yue JL, Goshima Y, et al. Non-effective dose of exogenously applied L-dopa itself stereoselectively potentiates postsynaptic D2 receptor-mediated locomotor activities of conscious rats. Neurosci Lett. 1994 ; 170: 22-26
37. Natesan S, Reckless GE, Nobrega JN, et al. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: Comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology. 2006 ; 31: 1854-1863
38. Noda Y, Yamada K, Furukawa H, et al. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: A new model of schizophrenia. Br J Pharmacol. 1995 ; 116: 2531-2537
39. Nordquist RE, Risterucci C, Moreau JL, et al. Effects of aripiprazole/opc-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Neuropharmacology. 2008 ; 54: 405-416
40. Peselmann N, Schmitt A, Gebicke-Haerter PJ, et al. Aripiprazole differentially regulates the expression of gad67 and gamma-aminobutyric acid transporters in rat brain. Eur Arch Psychiatry Clin Neurosci. 2013 ; 263: 285-297
41. Prosser ES, Pruthi R, Csernansky JG. Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride. Psychopharmacology (Berl). 1989 ; 99: 109-116
42. Qiao H, Noda Y, Kamei H, et al. Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport. 2001 ; 12: 11-15
43. Qiao J, Gao J, Shu Q, et al. Long-lasting sensitization induced by repeated risperidone treatment in adolescent Sprague-Dawley Rats: A possible D2 receptor mediated phenomenon?. Psychopharmacology (Berl). 2014 ; 231: 1649-1659
44. Qiao J, Li H, Li M. Olanzapine sensitization and clozapine tolerance: From adolescence to adulthood in the conditioned avoidance response model. Neuropsychopharmacology. 2013 ; 38: 513-524
45. Qin R, Chen Y, Li M. Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity. Neuropharmacology. 2013 ; 75C: 356-364
46. Remington G, Kapur S. Antipsychotic dosing: How much but also how often?. Schizophr Bull. 2010 ; 36: 900-903
47. Renoir T, Pang TY, Lanfumey L. Drug withdrawal-induced depression: Serotonergic and plasticity changes in animal models. Neurosci Biobehav Rev. 2012 ; 36: 696-726
48. Samaha AN, Reckless GE, Seeman P, et al. Less is more: Antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry. 2008 ; 64: 145-152
49. Samaha AN, Seeman P, Stewart J, et al. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007 ; 27: 2979-2986
50. Seeman P. Dopamine D2(high) receptors moderately elevated by bifeprunox and aripiprazole. Synapse. 2008 ; 62: 902-908
51. Seeman P, Weinshenker D, Quirion R, et al. Dopamine supersensitivity correlates with D2high states, implying many paths to psychosis. Proc Natl Acad Sci U S A. 2005 ; 102: 3513-3518
52. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003 ; 28: 1400-1411
53. Shu Q, Hu G, Li M. Adult response to olanzapine or clozapine treatment is altered by adolescent antipsychotic exposure: A preclinical test in the phencyclidine hyperlocomotion model. J Psychopharmacol. 2014 ; 28: 363-375
54. Spielewoy C, Markou A. Withdrawal from chronic phencyclidine treatment induces long-lasting depression in brain reward function. Neuropsychopharmacology. 2003 ; 28: 1106-1116
55. Sun T, Hu G, Li M. Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: Relevance to animal models of antipsychotic drugs. Eur J Pharmacol. 2009 ; 602: 334-342
56. Sun T, Zhao C, Hu G, et al. Iptakalim: A potential antipsychotic drug with novel mechanisms?. Eur J Pharmacol. 2010 ; 634: 68-76
57. Swalve N, Li M. Parametric studies of antipsychotic-induced sensitization in the conditioned avoidance response model: Roles of number of drug exposure, drug dose, and test-retest interval. Behav Pharmacol. 2012 ; 23: 380-391
58. Tadokoro S, Okamura N, Sekine Y, et al. Chronic treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr Bull. 2012 ; 38: 1012-1020
59. Turrone P, Remington G, Kapur S, et al. Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biol Psychiatry. 2005 ; 57: 406-411
60. Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (Opc 14597): A study using positron emission tomography and [11c]raclopride. Neuropsychopharmacology. 2002 ; 27: 248-259
61. Zhang C, Li M. Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine. Behav Pharmacol. 2012 ; 23: 66-79
62. Zhao C, Li M. Neuroanatomical substrates of the disruptive effect of olanzapine on rat maternal behavior as revealed by C-Fos immunoreactivity. Pharmacol Biochem Behav. 2012 ; 103: 174-180
63. Zhao C, Sun T, Li M. Neural basis of the potentiated inhibition of repeated haloperidol and clozapine treatment on the phencyclidine-induced hyperlocomotion. Prog Neuropsychopharmacol Biol Psychiatry. 2012 ; 38: 175-182
64. Zocchi A, Fabbri D, Heidbreder CA. Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex. Neurosci Lett. 2005 ; 387: 157-161